Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications

MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway

(2017) Hongyu Shen et al.   GENE

Breast cancer

(2017) Nadia Harbeck et al.   LANCET

Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials

(2017) Wen-Zhao Lin et al.   Breast Cancer

MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1

(2017) Qing Xie et al.   Oncotarget

Research needs in breast cancer

(2016) F. Cardoso et al.   ANNALS OF ONCOLOGY

Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling

(2016) Xin Xu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells

(2016) Xinfeng Yu et al.   BIOMEDICINE & PHARMACOTHERAPY

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

(2016) Nadia Harbeck et al.   BREAST CANCER RESEARCH AND TREATMENT

Generic oncology drugs: are they all safe?

(2016) Y Tony Yang et al.   LANCET ONCOLOGY

Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy

(2016) Zhen-Ru Liu et al.   LIFE SCIENCES

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1

(2016) L Venturutti et al.   ONCOGENE

MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3β/β-Catenin Signaling Pathway

(2016) Xiaohui Zhang et al.   PLoS One

Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression

(2016) Jiang Zhu et al.   Cell Death & Disease

A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment

(2016) F. Du et al.   Scientific Reports

MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel

(2015) He-da Zhang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin

(2015) Jianxin Lv et al.   BIOMEDICINE & PHARMACOTHERAPY

Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4

(2015) Aamir Ahmad et al.   BMC CANCER

MicroRNA expression profiling and bioinformatics analysis of dysregulated microRNAs in vinorelbine-resistant breast cancer cells

(2015) Shanliang Zhong et al.   GENE

Decrease of Let-7f in Low-Dose Metronomic Paclitaxel Chemotherapy Contributed to Upregulation of Thrombospondin-1 in Breast Cancer

(2015) Wei-Yang Tao et al.   International Journal of Biological Sciences

MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy

(2015) Xinfeng Yu et al.   Molecular Cancer

Towards a molecular understanding of microRNA-mediated gene silencing

(2015) Stefanie Jonas et al.   NATURE REVIEWS GENETICS

miR-520h is crucial for DAPK2 regulation and breast cancer progression

(2015) C-M Su et al.   ONCOGENE

Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer

(2015) J Niu et al.   ONCOGENE

miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression

(2015) YA-SAI YAO et al.   ONCOLOGY REPORTS

MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer

(2015) Zhen-Hua Wu et al.   TUMOR BIOLOGY

MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer

(2015) Haifei He et al.   TUMOR BIOLOGY

Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer

(2015) Zhiqiang Ye et al.   TUMOR BIOLOGY

MicroRNA-205 increases the sensitivity of docetaxel in breast cancer

(2015) YANG CAI et al.   Oncology Letters

MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer

(2015) Xiaoping Liu et al.   Oncotarget

miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response

(2015) Alessandra Cataldo et al.   Oncotarget

Micro RNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR

(2015) Baotong Zhang et al.   Oncotarget

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

(2015) Leticia De Mattos-Arruda et al.   Oncotarget

MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition

(2015) Yuan Zhang et al.   Scientific Reports

A MicroRNA Expression Signature In Taxane-anthracycline-Based Neoadjuvant Chemotherapy Response

(2015) Yi Zheng et al.   Journal of Cancer

Influence of MiR-451 on Drug Resistances of Paclitaxel-Resistant Breast Cancer Cell Line

(2015) Xi Gu et al.   MEDICAL SCIENCE MONITOR

microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers

(2015) Pierluigi Gasparini et al.   Oncotarget

miRNA expression patterns in chemoresistant breast cancer tissues

(2014) Jianxin Lv et al.   BIOMEDICINE & PHARMACOTHERAPY

Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R

(2014) Xing-Ming Ye et al.   BMC CANCER

Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer

(2014) Hans-Joachim Lück et al.   BREAST CANCER RESEARCH AND TREATMENT

Loss of Estrogen-Regulated microRNA Expression Increases HER2 Signaling and Is Prognostic of Poor Outcome in Luminal Breast Cancer

(2014) S. T. Bailey et al.   CANCER RESEARCH

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

(2014) Evandro de Azambuja et al.   LANCET ONCOLOGY

miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

(2014) Claire Corcoran et al.   Molecular Cancer

Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial–mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells

(2014) R L Carpenter et al.   ONCOGENE

MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer

(2014) Mao Ouyang et al.   PLoS One

Circulating miR-19a and miR-205 in Serum May Predict the Sensitivity of Luminal A Subtype of Breast Cancer Patients to Neoadjuvant Chemotherapy with Epirubicin Plus Paclitaxel

(2014) Qian Li et al.   PLoS One

MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells

(2014) Qing Hu et al.   TUMOR BIOLOGY

MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1

(2014) Xiao He et al.   TUMOR BIOLOGY

Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs

(2014) Wei-xian Chen et al.   TUMOR BIOLOGY

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

(2013) Lucia Del Mastro et al.   BMC CANCER

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

(2013) Howard A. Burris   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8

(2013) Z. C. Hartman et al.   CANCER RESEARCH

Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment

(2013) Reiner Hoppe et al.   EUROPEAN JOURNAL OF CANCER

Chemotherapy regimens in early breast cancer: major controversies and future outlook

(2013) Markus Joerger et al.   Expert Review of Anticancer Therapy

miR-222 and miR-29a contribute to the drug-resistance of breast cancer cells

(2013) Shanliang Zhong et al.   GENE

The Overexpression of Hypomethylated miR-663 Induces Chemotherapy Resistance in Human Breast Cancer Cells by Targeting Heparin Sulfate Proteoglycan 2 (HSPG2)

(2013) Haiyan Hu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer

(2013) Zhongzhen Guan et al.   JOURNAL OF CLINICAL ONCOLOGY

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

(2013) Helena M Earl et al.   LANCET ONCOLOGY

5-FU and ixabepilone modify the microRNA expression profiles in MDA-MB-453 triple-negative breast cancer cells

(2013) YONGSHAN YAO et al.   Oncology Letters

The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer

(2012) Rabia A. Gilani et al.   BREAST CANCER RESEARCH AND TREATMENT

Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials

(2012) Wei-Xiang Qi et al.   CURRENT MEDICAL RESEARCH AND OPINION

Chemotherapy-Resistant Metastatic Breast Cancer

(2012) Carrie Marquette et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies

(2012) Lidia Rita Corsini et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Lin28 Mediates Paclitaxel Resistance by Modulating p21, Rb and Let-7a miRNA in Breast Cancer Cells

(2012) Kezhen Lv et al.   PLoS One

Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer

(2012) Thuy Vu et al.   Frontiers in Oncology

miRNA-34a is associated with docetaxel resistance in human breast cancer cells

(2011) L. Kastl et al.   BREAST CANCER RESEARCH AND TREATMENT

Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients

(2011) Eun-Jung Jung et al.   CANCER

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer

(2011) Maurizio Belfiglio et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

(2011) Meredith M Regan et al.   LANCET ONCOLOGY

Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer

(2011) Françoise Rothé et al.   PLoS One

MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer

(2010) F. Germán Rodríguez-González et al.   BREAST CANCER RESEARCH AND TREATMENT

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin

(2010) Igor P. Pogribny et al.   INTERNATIONAL JOURNAL OF CANCER

MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression

(2010) Ming Zhou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways

(2010) X Rao et al.   ONCOGENE

MicroRNA Regulation of DNA Repair Gene Expression in Hypoxic Stress

(2009) M. E. Crosby et al.   CANCER RESEARCH

Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer

(2009) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

(2009) Francisco J. Esteva et al.   Nature Reviews Clinical Oncology

Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3

(2008) Wing Pui Tsang et al.   APOPTOSIS

Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin

(2008) O. Kovalchuk et al.   MOLECULAR CANCER THERAPEUTICS